Cargando…
In Vivo Fluorescence Lifetime Imaging Monitors Binding of Specific Probes to Cancer Biomarkers
One of the most important factors in choosing a treatment strategy for cancer is characterization of biomarkers in cancer cells. Particularly, recent advances in Monoclonal Antibodies (MAB) as primary-specific drugs targeting tumor receptors show that their efficacy depends strongly on characterizat...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3285647/ https://www.ncbi.nlm.nih.gov/pubmed/22384092 http://dx.doi.org/10.1371/journal.pone.0031881 |
_version_ | 1782224500164657152 |
---|---|
author | Ardeshirpour, Yasaman Chernomordik, Victor Zielinski, Rafal Capala, Jacek Griffiths, Gary Vasalatiy, Olga Smirnov, Aleksandr V. Knutson, Jay R. Lyakhov, Ilya Achilefu, Samuel Gandjbakhche, Amir Hassan, Moinuddin |
author_facet | Ardeshirpour, Yasaman Chernomordik, Victor Zielinski, Rafal Capala, Jacek Griffiths, Gary Vasalatiy, Olga Smirnov, Aleksandr V. Knutson, Jay R. Lyakhov, Ilya Achilefu, Samuel Gandjbakhche, Amir Hassan, Moinuddin |
author_sort | Ardeshirpour, Yasaman |
collection | PubMed |
description | One of the most important factors in choosing a treatment strategy for cancer is characterization of biomarkers in cancer cells. Particularly, recent advances in Monoclonal Antibodies (MAB) as primary-specific drugs targeting tumor receptors show that their efficacy depends strongly on characterization of tumor biomarkers. Assessment of their status in individual patients would facilitate selection of an optimal treatment strategy, and the continuous monitoring of those biomarkers and their binding process to the therapy would provide a means for early evaluation of the efficacy of therapeutic intervention. In this study we have demonstrated for the first time in live animals that the fluorescence lifetime can be used to detect the binding of targeted optical probes to the extracellular receptors on tumor cells in vivo. The rationale was that fluorescence lifetime of a specific probe is sensitive to local environment and/or affinity to other molecules. We attached Near-InfraRed (NIR) fluorescent probes to Human Epidermal Growth Factor 2 (HER2/neu)-specific Affibody molecules and used our time-resolved optical system to compare the fluorescence lifetime of the optical probes that were bound and unbound to tumor cells in live mice. Our results show that the fluorescence lifetime changes in our model system delineate HER2 receptor bound from the unbound probe in vivo. Thus, this method is useful as a specific marker of the receptor binding process, which can open a new paradigm in the “image and treat” concept, especially for early evaluation of the efficacy of the therapy. |
format | Online Article Text |
id | pubmed-3285647 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-32856472012-03-01 In Vivo Fluorescence Lifetime Imaging Monitors Binding of Specific Probes to Cancer Biomarkers Ardeshirpour, Yasaman Chernomordik, Victor Zielinski, Rafal Capala, Jacek Griffiths, Gary Vasalatiy, Olga Smirnov, Aleksandr V. Knutson, Jay R. Lyakhov, Ilya Achilefu, Samuel Gandjbakhche, Amir Hassan, Moinuddin PLoS One Research Article One of the most important factors in choosing a treatment strategy for cancer is characterization of biomarkers in cancer cells. Particularly, recent advances in Monoclonal Antibodies (MAB) as primary-specific drugs targeting tumor receptors show that their efficacy depends strongly on characterization of tumor biomarkers. Assessment of their status in individual patients would facilitate selection of an optimal treatment strategy, and the continuous monitoring of those biomarkers and their binding process to the therapy would provide a means for early evaluation of the efficacy of therapeutic intervention. In this study we have demonstrated for the first time in live animals that the fluorescence lifetime can be used to detect the binding of targeted optical probes to the extracellular receptors on tumor cells in vivo. The rationale was that fluorescence lifetime of a specific probe is sensitive to local environment and/or affinity to other molecules. We attached Near-InfraRed (NIR) fluorescent probes to Human Epidermal Growth Factor 2 (HER2/neu)-specific Affibody molecules and used our time-resolved optical system to compare the fluorescence lifetime of the optical probes that were bound and unbound to tumor cells in live mice. Our results show that the fluorescence lifetime changes in our model system delineate HER2 receptor bound from the unbound probe in vivo. Thus, this method is useful as a specific marker of the receptor binding process, which can open a new paradigm in the “image and treat” concept, especially for early evaluation of the efficacy of the therapy. Public Library of Science 2012-02-23 /pmc/articles/PMC3285647/ /pubmed/22384092 http://dx.doi.org/10.1371/journal.pone.0031881 Text en This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication. https://creativecommons.org/publicdomain/zero/1.0/ This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration, which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. |
spellingShingle | Research Article Ardeshirpour, Yasaman Chernomordik, Victor Zielinski, Rafal Capala, Jacek Griffiths, Gary Vasalatiy, Olga Smirnov, Aleksandr V. Knutson, Jay R. Lyakhov, Ilya Achilefu, Samuel Gandjbakhche, Amir Hassan, Moinuddin In Vivo Fluorescence Lifetime Imaging Monitors Binding of Specific Probes to Cancer Biomarkers |
title |
In Vivo Fluorescence Lifetime Imaging Monitors Binding of Specific Probes to Cancer Biomarkers |
title_full |
In Vivo Fluorescence Lifetime Imaging Monitors Binding of Specific Probes to Cancer Biomarkers |
title_fullStr |
In Vivo Fluorescence Lifetime Imaging Monitors Binding of Specific Probes to Cancer Biomarkers |
title_full_unstemmed |
In Vivo Fluorescence Lifetime Imaging Monitors Binding of Specific Probes to Cancer Biomarkers |
title_short |
In Vivo Fluorescence Lifetime Imaging Monitors Binding of Specific Probes to Cancer Biomarkers |
title_sort | in vivo fluorescence lifetime imaging monitors binding of specific probes to cancer biomarkers |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3285647/ https://www.ncbi.nlm.nih.gov/pubmed/22384092 http://dx.doi.org/10.1371/journal.pone.0031881 |
work_keys_str_mv | AT ardeshirpouryasaman invivofluorescencelifetimeimagingmonitorsbindingofspecificprobestocancerbiomarkers AT chernomordikvictor invivofluorescencelifetimeimagingmonitorsbindingofspecificprobestocancerbiomarkers AT zielinskirafal invivofluorescencelifetimeimagingmonitorsbindingofspecificprobestocancerbiomarkers AT capalajacek invivofluorescencelifetimeimagingmonitorsbindingofspecificprobestocancerbiomarkers AT griffithsgary invivofluorescencelifetimeimagingmonitorsbindingofspecificprobestocancerbiomarkers AT vasalatiyolga invivofluorescencelifetimeimagingmonitorsbindingofspecificprobestocancerbiomarkers AT smirnovaleksandrv invivofluorescencelifetimeimagingmonitorsbindingofspecificprobestocancerbiomarkers AT knutsonjayr invivofluorescencelifetimeimagingmonitorsbindingofspecificprobestocancerbiomarkers AT lyakhovilya invivofluorescencelifetimeimagingmonitorsbindingofspecificprobestocancerbiomarkers AT achilefusamuel invivofluorescencelifetimeimagingmonitorsbindingofspecificprobestocancerbiomarkers AT gandjbakhcheamir invivofluorescencelifetimeimagingmonitorsbindingofspecificprobestocancerbiomarkers AT hassanmoinuddin invivofluorescencelifetimeimagingmonitorsbindingofspecificprobestocancerbiomarkers |